Lantheus Holdings stock
LNTHNASDAQLantheus Holdings, Inc., HealthcareISIN US5165441032
76Score 76 out of 100, Strong
Price and trend
80 / 100
Price history
+86% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 8.9% above it.
Since February 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 70).
The price is 8.7% below its 52-week high. Largest decline in 11 years: 79% (August 2015 to February 2016).
Chart figures for advanced users
- SMA 50$100.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$92.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$52.50
- The lowest closing price of the last twelve months.
- Resistance$110.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lantheus Holdings, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $6.62B, is number 37 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.54B (up 0.5% year on year) and earnings of $233.56M (down 25.2%).
- For fiscal 2026, analysts expect on average revenue of $1.47B (down 4.8%) and adjusted earnings per share of $5.36 (down 11.2%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 53 of 714 in Healthcare, median 53.
- The P/E is 25.7 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 17).
- Our model puts fair value at $118.48, with the price 14% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 35.3% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 83
- Earnings turn into cashFree cash flow 146% of earnings over the last 12 months.Fundamentals 86
- High return on capitalReturn on invested capital 21.6% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 83
Weaknesses
- DilutionShare count up 25% since 2020.Capital allocation 47
- Richly valuedP/E 25.7, Drug Manufacturers (Specialty & Generic) median 19.3, own median 17.Valuation 59
Its standout strengths are fundamentals and growth, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $84.63 and expensive above $197.46 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $160.65 (cash-flow model) and $76.30 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $104.24, at 7.8% it would be $139.89.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.4% on the twelve months before. Revenue has grown solidly since 2011, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating 20%, net 15%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $1.68 (expected $1.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.36−1.0%
- Revenue
- $1.47B−1.1%
- Earnings per share
- $6.46+0.8%
- Revenue
- $1.64B−1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +8.0%2026 guidance reiterated: revenue of $1.4 billion to $1.45 billion, adjusted EPS of $5 to $5.25.
“As such, our full year forecasted revenue remains at $1.4 billion to $1.45 billion for 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Lantheus Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- AlkermesALKS $8.05B53
- Amneal PharmaceuticalsAMRX $7.56B57
- Huadong Medicine000963.SZ $6.98B62
- Alkem LaboratoriesALKEM.NS $6.95B65
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Apotex HealthAPTX.TO $5.78B70
- Gland PharmaGLAND.NS $5.75B70
- Sumitomo Pharma4506.T $5.45B57
ETFs that hold Lantheus Holdings
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.64% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.49% | 0.40% | €807M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.48% | 0.39% | €1.47B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.22% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.22% | 0.30% | €2.17B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.20% | 0.30% | €5.27B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.12% | 0.39% | €188.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.